BiotechTube
Eurogentec

Eurogentec

Liège, Belgium· Est.
eurogentec.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Eurogentec is a long-established, privately-held Belgian CDMO and product supplier serving the global life sciences industry. It has strategically evolved from a research reagent provider into a full-service partner for therapeutic development, with a strong focus on nucleic acid manufacturing (plasmids and mRNA) and high-quality oligos for diagnostics. The company is capitalizing on the mRNA and advanced therapy boom, having recently completed a commercial-scale mRNA manufacturing facility, positioning it as a key European player in the bioproduction space. Its business model blends high-margin research products with scalable, regulated CDMO services.

Biologics

Technology Platform

Integrated platform for oligonucleotide synthesis, GMP manufacturing of plasmid DNA, recombinant proteins, antibody fragments, and mRNA. Capabilities span from research-grade reagents to commercial-scale therapeutic production.

Funding History

1
UndisclosedUndisclosed

Opportunities

The explosive growth of mRNA therapeutics and vaccines post-COVID-19 creates massive demand for GMP manufacturing capacity, where Eurogentec's new commercial-scale facility positions it as a key European supplier.
Additionally, the continued expansion of gene and cell therapies drives long-term demand for high-quality plasmid DNA, a core competency of the company.

Risk Factors

Revenue is dependent on the success of client drug programs, exposing the company to pipeline attrition risk.
The capital-intensive CDMO market is fiercely competitive, requiring constant investment to keep pace with larger players.
Operational risks include potential manufacturing failures or regulatory issues that could damage its trusted partner reputation.

Competitive Landscape

Eurogentec competes with large, global CDMOs like Lonza, Catalent, and Thermo Fisher Scientific, as well as specialized nucleic acid-focused players like TriLink BioTechnologies and Aldevron. Its differentiation lies in its integrated offering of research products and CDMO services, deep oligonucleotide expertise, and its strategic position as a mid-sized, European-based alternative with recently built, state-of-the-art mRNA capacity.

More companies in Biologics / Biosimilars →More companies in Belgium →